BioNTech is positioning 2026 as a defining year in its transition toward a multi-product oncology company
The partnership will launch a Phase 1b cohort within Boehringer’s ongoing Beamion-BCGC1 trial
The company is rolling out ARTEMIS, a next-generation AI platform for capsid design
Iktos will deploy its AI-driven tools to accelerate the identification of optimized small-molecule candidates against a currently undisclosed oncology target
GRIN-NDD is one of the most complex neurodevelopmental disorders with limited treatment options today
The acquisition of AT-01 (124-Iodine-evuzamitide) and AT-05 (PAR-Peptide + technetium-99m) positions Bayer at the forefront of cardiac amyloidosis diagnostics
Artificial intelligence coupled with laboratory automation will transform how scientific work is performed
Projects selected for advancement will move forward through the Harvard Office of Technology Development’s processes for sponsored research agreements
Gefion, powered entirely by renewable energy, boasts more than 1,500 NVIDIA GPUs
Subscribe To Our Newsletter & Stay Updated